4 ms·
> I mean, just take a look at uniprot.[0] this looks like one narrow niche knowledge base. I am not expert in this domain, but there are probably some other us
by riku_iki 3y ago
> I mean, just take a look at uniprot.[0]
this looks like one narrow niche knowledge base. I am not expert in this domain, but there are probably some other use cases not covered by existing offerings.
> literature extraction - because a team of 5-10 FTE ML / software engineers
I think this problem is so hard and open ended, that your 5-10 non-star avg salary ml ftes likely produce very mediocre and likely not usable results.
- radus 3y ago> this looks like one narrow niche knowledge base. I am not expert in this domain, but there are probably some other use cases not covered by existing offerings. UniProt is not niche. It contains curated information about all proteins across numerous domains.
- riku_iki 3y agoyes, proteins is a niche in grand scheme of things
- pama 3y agoThe GP was talking about pharma. Proteins are not niche in pharma. Everything else may be niche in that domain, but proteins make up more than 95% of the targets of the pharmaceutical industry.
- dekhn 3y agoand an increasing number of drugs- in the "old days" it was almost entirely small molecules, but they are starting to peter out (both because the low-hanging fruit has already been plucked, and also, small molecules are a usually a terrible way to modulate biological activity in specific ways.
- riku_iki 3y ago> The GP was talking about pharma. post is not about pharma specifically, but about general bio-medical literature, including genes, diseases, symptoms, etc. > proteins make up more than 95% of the targets of the pharmaceutical industry. do you have references to support this? Some google search says it is 280B market out of 1.5T total pharma market: https://www.alliedmarketresearch.com/protein-therapeutics-market https://www.alliedmarketresearch.com/protein-therapeutics-ma... https://www.statista.com/topics/1764/global-pharmaceutical-industry/#topicOverview https://www.statista.com/topics/1764/global-pharmaceutical-i... Also, it is likely important steps how to research and produce protein drugs, but the end target is to cure diseases, so you need lots of additional data about diseases of all types, symptoms, pathways, trials, etc.
- dekhn 3y agoThis isn't a "do you have references" situation. You're wasting folks time. Nearly all drugs target proteins, with a few that target DNA or RNA.
- riku_iki 3y agoYou can just ignore my comments and walk away? To me you just another "internet expert" which I am not sure why should I blindly trust.
- myownpetard 3y agoYour sources are talking about the ratio of small molecule vs. large molecule drugs. Even if you're developing small molecule drugs you are likely targeting some aspect of protein signaling/gene expression. People are being dismissive of your comments because to say that proteins are niche in the context of pharma is like saying advertising is niche in the context of Meta and Google.
- riku_iki 3y ago> People are being dismissive of your comments because to say that proteins are niche in the context of pharma is like saying advertising is niche in the context of Meta and Google. its all about how you define word "niche", for google, main revenue stream is supported by several pillars: search tech, infra tech, ads tech, ecosystem+network effect, human management. You remove one pillar, and everything is destroyed, so one can say ads is one of the niches in their food chain. I suspect with proteins it is about the same. > in the context of pharma there is no context of pharma. Post is about more broad bio-medical publications.
- pfisherman 3y agoUniprot fills a pretty big niche - proteins. Your body is literally made out of proteins. They carry out most of the work and chemical reactions that amount to what we call life, and almost all drugs work by modulating some protein target in some way. UniprotIDs are the canonical identifiers that computational biologists use for proteins. But they are just one knowledge base. There are others. Each with their own focus area. And they are all associated with prominent bioNLP / biomedical AI research labs and employ human SME curators. > 5-10 avg salary non-star ML FTEs likely produce very mediocre and likely non usable results LOL!
- riku_iki 3y ago> But they are just one knowledge base. There are others. So, is your claim that all topics/niches/verticals/steps in pharma development and productions are covered by all those databases with absolute quality and perfect UI/workflow? I follow some studies about trials meta-analysis, and my impression is that end result is mainly produced by manual work of some low paid postdocs, which makes them not trustworthy. > LOL! I actually claim non-trivial expertise in this area (facts extraction from untrivial niche documents), and my observations is that even SOTA (aka results from top researchers) are hardly useable in real life, because this area is very hard. Could you support your "LOL!" with any references I could check?..
- MichaelZuo 3y agoThe parent is right, saying a database about proteins 'looks like one narrow niche knowledge base.' in this context is just nonsense.
- riku_iki 3y agoin which context, and why your bold statements should be trusted blindly?
- deleted 3y ago[deleted]